.tb-field[data-toolset-blocks-field="ec0a35e9fb83f62f51b6d4f9a837b99f"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="c93f21c8efcbfaa5870cd8f93f03ae2c"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="c35d9a7279448f10d949ebc7e457ae45"] { text-align: left;justify-content: flex-start; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { background-color: rgba( 217, 217, 217, 0.13 );padding: 10px;margin-bottom: 15px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 215, 213, 213, 1 );grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-field[data-toolset-blocks-field="627e912eb953c8ed786ea0c7e10207ea"] { font-size: 14px;text-align: left;padding: 0px;margin: 0px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }   h1.tb-heading[data-toolset-blocks-heading="4273ccf7ca31e5697065fdb41a036bd2"]  { font-size: 26px; }  .wpv-custom-search-filter-submit[data-toolset-views-custom-search-submit="8ca7a9b3f80df5aa18fe74ad2a58d731"] { text-align: left; } @media only screen and (max-width: 781px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } @media only screen and (max-width: 599px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } 

News and Press Releases

Awen Oncology secures significant new funds to advance pioneering cancer therapeutics

23 April 2026 -- Anglesey, UK -- Awen Oncology, a pioneering Wales-based therapeutics company developing next-generation cancer treatments, has secured funds from a number of sources, worth seven figures, which...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2026

Awen Oncology

CWOW 2026: Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

26 March 2026 -- Cambridge, UK -- Cambridge Wide Open Week (CWOW) returns 11–19 June 2026, sharing the spirit and buzz of the week-long,interactive festival with Oxford and London for...

Category: Drug Discovery, Other, Pharmaceutical
Posted: March 26, 2026

o2h

info@o2h.com

Mill SciTech Park, Mill Lane Hauxton, Cambridge CB22 5HX

OBN Invites Life Science Leaders to Celebrate 20 Years of BioTrinity

Featuring keynotes from: Steve Bates, Executive Chair at the Office for Life Sciences, Lawrence Tallon, CEO at the MHRA & Maria Koufali, Life Sciences Industry Director at the NIHR, click...

Category: Other, Pharmaceutical
Posted: March 3, 2026

OBN

info@obn.org.uk

Unit 6 Library Avenue, Harwell, Didcot, OX11 0SG, UK

BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure

Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds Aurase shows dual action on chronic wound debridement and healing SolasCure preparing fund raising for...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 25, 2026

BRAINBiotech

public@brain-biotech.com

Darmstädter Straße 34 – 36 64673 Zwingenberg Deutschland

PMGroup Worldwide Ltd, a wholly owned subsidiary of Datateam Business Media Ltd, adds Laboratory News to publications portfolio

24 February 2026 -- London, UK -- PMGroup Worldwide Ltd are pleased to announce the acquisition of Laboratory News magazine and website, together with Laboratory Talk website, from Synthesis Media. Laboratory News has for...

Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 24, 2026

PMGroup Worldwide Ltd

info@pmlive.com

Mansard House, Church Road, Little Bookham, Leatherhead, Surrey, KT23 3JG

Title21 Hosts Inaugural Advisory Council Meeting to Drive Development of Interoperable CGT Software Tools

Diverse stakeholders from across the industry gathered alongside Title21’s senior leadership to identify the greatest challenges across the CGT sector The discussion highlighted a lack of interoperability causing unnecessary delays ...

Category: Drug Discovery, Other, Pharmaceutical
Posted: October 9, 2025

Title21

info@title21.com

2325 E. Camelback Rd., Suite 320 Phoenix, AZ 85016

SeaBeLife secures €2 million

This funding will help fast-track the launch of clinical trials in dry AMD and severe acute hepatitis programs 1 October 2025 -- Roscoff, France -- SeaBeLife, a biotechnology company developing...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025

SeaBeLife

contact@seabelife.com

Place Georges Teissier 29680 ROSCOFF

PACE launches its third funding round today, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to global health

1 October 2025 -- Alderley Park, UK -- To stay ahead of the escalating antibiotic resistance crisis, we need bold thinking and transformative innovation. According to the World Health Organization...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025

PACE

PlasmidFactory founder Dr. Martin Schleef honored with the NRW Innovation Award 2025

8 September 2025 -- Düsseldorf/Bielefeld, Germany -- The founder and long-standing CEO of PlasmidFactory GmbH, Dr. Martin Schleef, was honored today in Düsseldorf with the Innovation Award 2025 of the...

Category: BioManufacturing, Other, Pharmaceutical
Posted: September 8, 2025

PlasmidFactory GmbH & Co. KG

info@plasmidfactory.com

Meisenstraße 96, D-33607 Bielefeld, Germany

EVERSANA Announces Development of End-to-End AI-Powered Life Sciences Marketing Agency Built on Google Cloud Technology

4 August 2025 -- Illinois, US -- EVERSANA, a leading provider of commercialization services to the global life sciences industry, today launched a groundbreaking pharmaceutical marketing AI agency running on...

Category: Other, Pharmaceutical
Posted: August 4, 2025

Eversana

404 S. Wells Street, Chicago, IL 60607

BIO-Europe® 2025 Gathers Global Life Sciences Leaders in Vienna

2 July 2025 -- Munich, Germany -- The 31st annual edition of BIO-Europe, the premier partnering conference for the global biopharmaceutical industry, will take place in Vienna, Austria, from November...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 2, 2025

BIO-Europe 2025

EBDcustomerservice@ebdgroup.com

Central Research Laboratories Launches Single-Use Gamma Bags for Biopharma and Life Sciences Applications

25 March 2025 -- Minnesota, US -- Central Research Laboratories (CRL), a global leader in the remote-handling industry, is launching Single-Use Gamma Bags that have been designed to undergo gamma-sterilization...

Category: Biotechnology, Logistics, Other, Pharmaceutical
Posted: March 25, 2025

Central Research Laboratories

info@crlsolutions.com

3965 Pepin Avenue Red Wing, MN 55066

Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing

Bioxodes raises €2.7 million from existing investors in Series A extension Interim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial in Q1 2025 Recruitment of up to 16 additional...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 12, 2025

Bioxodes

info@bioxodes.com

Parc d'activités Aéropole Rue Santos-Dumont, 1 6041 Gosselies, Belgique

Italian roots, global reach: Biotech investment insights — a dynamic conversation with Graziano Seghezzi and Francesco De Rubertis

Get ready to ignite your BIO- Europe Spring 2025 experience with Graziano Seghezzi of Sofinnova Partners and Francesco De Rubertis of Medicxi, as they take the stage to set the...

Category: Other
Posted: December 19, 2024

BIO-Europe Spring 2025

EBDcustomerservice@ebdgroup.com

CCIB Barcelona Plaça de Willy Brandt 11-14 08019 Barcelona Spain

ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics

Brings 2024 Funding Round Total to €24m 16 December 2024 -- Milan, Italy -- BetaGlue Therapeutics S.p.A, an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: December 16, 2024